OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Study Identifier
GMA-OAB-113
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
  • Study Drug
  • onabotulinumtoxinA
  • Normal saline
  • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with an anticholinergic.

    Study Locations

    Location
    Status
    Location
    Urologic Clinics of North Alabama
    Huntsville, Alabama, United States, 35801
    Status
    Not applicable
    Location
    Alaska Urological Institute dba Alaska Clinical Research Center
    Anchorage, Alaska, United States, 99503
    Status
    Not applicable
    Location
    South Orange County Medical Research Center
    Laguna Hills, California, United States, 92653
    Status
    Not applicable
    Location
    University of Southern California
    Los Angeles, California, United States, 90033
    Status
    Not applicable
    Location
    Genesis Research LLC
    San Diego, California, United States, 92123
    Status
    Not applicable
    Location
    U. Colorado, School of Med.
    Aurora, Colorado, United States, 80045
    Status
    Not applicable
    Showing {first} - {last} of {total} Results